ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, and Molecular Targeting Technologies Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, today announced the signing of a global clinical supply agreement that provides MTTI with ITM’s medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu / EndolucinBeta®) for the preclinical and clinical development as well as potential commercial production of MTTI’s radiopharmaceutical candidate n.c.a. 177Lu-EBTATE to treat a range of cancers.

N.c.a. 177Lu-EBTATE is currently in the clinical development for the treatment of neuroendocrine tumors, a special form of thyroid cancer (Hürthle cell) and a rare type of head and neck cancer (nasopharyngeal cancer). The radiopharmaceutical is designed to be used in Targeted Radionuclide Therapy, a highly precise approach to directly target and destroy tumor tissue with minimal impact to surrounding healthy tissue. N.c.a. 177Lu-EBTATE consists of a tumor-targeting molecule and ITM’s medical radioisotope n.c.a. 177Lu, a market-approved, highly pure form of the beta-emitting radioisotope lutetium-177. N.c.a. 177Lu can be linked to a variety of tumor-specific targeting molecules for the treatment of various cancers and has been successfully used in numerous clinical and commercial radiopharmaceutical cancer treatments.

The agreement was executed between MTTI and ITM’s wholly-owned subsidiary ITM Medical Isotopes GmbH.

To read more please visit:

ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177

Source: ITM